Electrical stimulation and gene-based neuromodulation for control of medically-refractory epilepsy.
The failure of available antiepileptic medications to adequately control seizures in a substantial number of patients underscores the need to develop novel epilepsy therapies. Recent advancements in technology and the success of neuromodulation in treating a variety of neurological disorders have spurred interest in exploring promising therapeutic alternatives, such as electrical stimulation and gene-based synaptic control. A variety of different stimulation approaches to seizure control targeting structures in the central or peripheral nervous system have been investigated. Most studies have been based on uncontrolled observations and empirical stimulation protocols. Today the vagus nerve stimulator is the only FDA approved adjunctive treatment for epilepsy that utilizes electrical stimulation. Other potential strategies including direct stimulation of the epileptogenic cortex and deep brain stimulation of various targets are currently under investigation. Chronically implanted devices for electrical stimulation have a variety of limitations. First, they are susceptible to malfunction and infection. Second, most systems require battery replacement. Finally, electrical stimulation is incapable of manipulating neuronal function in a transmitter specific fashion. Gene delivery to epileptogenic targets or targets implicated in regulating seizure threshold has been investigated as an alternative means of neuromodulation in animal models. In summary, positive preliminary results and the lack of alternative treatment options provide the impetus for further exploration of electrical stimulation and gene-based therapies in pharmacoresistant epilepsy. Various specific targets and approaches to modulating their activity have been investigated in human studies.
Alexopoulos
A V
AV
Department of Neurology, Section of Adult Epilepsy, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Gonugunta
V
V
Yang
J
J
Boulis
N M
NM
D000818:Animals; D004558:Electric Stimulation / Q000295:instrumentation / Q000379:methods*; D004827:Epilepsy / Q000473:pathology / Q000628:therapy*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D009419:Nerve Tissue Proteins / Q000096:biosynthesis / Q000627:therapeutic use; D009420:Nervous System / Q000503:physiopathology; D050781:Transcranial Magnetic Stimulation / Q000379:methods
D009419:Nerve Tissue Proteins